Drugs / Personalized Synthetic Long Peptide Vaccine
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02427581 | Sep 2015 → Dec 2025 | triple-negative breast carcinoma | Washington University School of Medicine | Withdrawn | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05741242 | Nov 2022 → Jan 2027 expected | cancer | Jaime Leandro Foundation for Therapeutic Cancer Vaccines | Enrolling by invitation | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03606967 | Apr 2021 → Dec 2026 expected | invasive breast carcinoma, triple-negative breast carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT06963697 | — | cancer | Jaime Leandro Foundation for Therapeutic Cancer Vaccines | Available | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Personalized Synthetic Long Peptide Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03606967 ↗ |
| Modality | Vaccine | “synthetic long peptide vaccine” NCT02427581 ↗ |
| Route | Subcutaneous | “by subcutaneous (SC) injection” NCT02427581 ↗ |